The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Patients who undergo bariatric surgery often have inadequate weight loss or weight regain. Objectives: We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. Setting: Two academic medical centers. Methods: We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000– 2014. From this cohort, we identified patients who were placed on weight loss pharmacotherapy postoperatively for inadequate weight loss or weight regain. We extracted key demographic data, medical history, and examined weight loss in response to surgery and after the initiation of weight loss pharmacotherapy. Results: A total of 319 patients (RYGB = 258; sleeve gastrectomy =61) met inclusion criteria for analysis. More than half (54%; n = 172) of all study patients lost ≥5% (7.2 to 195.2 lbs) of their total weight with medications after surgery. There were several high responders with 30.3% of patients (n = 96) and 15% (n = 49) losing ≥10% (16.7 to 195.2 lbs) and ≥15% (25 to 195.2 lbs) of their total weight, respectively, Topiramate was the only medication that demonstrated a statistically significant response for weight loss with patients being twice as likely to lose at least 10% of their weight when placed on this medication (odds ratio 1.9; P .018). Regardless of the postoperative body mass index, patients who underwent RYGB were significantly more likely to lose ≥5% of their total weight with the aid of weight loss medications. Conclusions: Weight loss pharmacotherapy serves as a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. (Surg Obes Relat Dis 2017;13:491–501.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“factors, including triglycerides levels, blood pressure, and blood glucose levels.[37, 38]”
BackgroundPrevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Chang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Obesity · doi:10.1002/oby.20461 · Cited by 1,650
Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2014) · JAMA · doi:10.1001/jama.2014.5988 · Cited by 1,054 · cited 1×
“9) and severe obesity (BMI ≥ 40).[3-5] Patients often experience complete”
BackgroundWeight Recidivism Post-Bariatric Surgery: A Systematic Review
Karmali, S., Brar, B., Shi, X., Sharma, A. M., de Gara, C., & Birch, D. W. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1070-4 · Cited by 574
Behavioral predictors of weight regain after bariatric surgery
Odom, J., Zalesin, K. C., Washington, T. L., Miller, W. W., Hakmeh, B., Zaremba, D. L., Altattan, M., Balasubramaniam, M., Gibbs, D. S., Krause, K. R., et al. (2010) · Obesity Surgery · doi:10.1007/s11695-009-9895-6 · Cited by 483
Cited by
ASMBS pediatric metabolic and bariatric surgery guidelines, 2018
Pratt, J. S. A., Browne, A., Browne, N. T., Bruzoni, M., Cohen, M., Desai, A., Inge, T., Linden, B. C., Mattar, S. G., Michalsky, M., et al. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.03.019 · Cited by 555
Self-citationEl Ansari, W., & Elhag, W. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05160-5 · Cited by 482
“In the same study, regardless of the postoperative BMI, RYGB patients were significantly more likely to lose ≥ 5% of their weight with medications [95].”
BackgroundMethodInfluentialBusetto, L., Dicker, D., Azran, C., Batterham, R. L., Farpour-Lambert, N., Fried, M., Hjelmesæth, J., Kinzl, J., Leitner, D. R., Makaronidis, J. M., et al. (2017) · Obesity Facts · doi:10.1159/000481825 · Cited by 437
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment
Noria, S. F., Shelby, R. D., Atkins, K. D., Nguyen, N. T., & Gadde, K. M. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01498-z · Cited by 223
Wharton, S., Kuk, J. L., Luszczynski, M., Kamran, E., & Christensen, R. A. G. (2019) · Clinical Obesity · doi:10.1111/cob.12323 · Cited by 144
“The studies which have primarily examined the use of phentermine, phentermine/topiramate, and naltrexone/bupropion, and report no differences for patients who had undergone RNYGB and AGB.”
ResultInfluentialGomez, G., & Stanford, F. C. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.287 · Cited by 128
Self-citationHorn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114
“Combining AOMs with bariatric surgery may also be beneficial to maintain weight loss and avoid weight regain in some patients [53,54].”
BackgroundDescribing the Weight‐Reduced State: Physiology, Behavior, and Interventions
Aronne, L. J., Hall, K. D., M. Jakicic, J., Leibel, R. L., Lowe, M. R., Rosenbaum, M., & Klein, S. (2021) · Obesity · doi:10.1002/oby.23086 · Cited by 113
“2%) in patients who started pharmacotherapy after weight regain (136).”
BackgroundSelf-citationRye, P., Modi, R., Cawsey, S., & Sharma, A. M. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3393-7 · Cited by 97
Efficacy of adjuvant weight loss medication after bariatric surgery
Nor Hanipah, Z., Nasr, E. C., Bucak, E., Schauer, P. R., Aminian, A., Brethauer, S. A., & Cetin, D. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.10.002 · Cited by 93
Murvelashvili, N., Xie, L., Schellinger, J. N., Mathew, M. S., Marroquin, E. M., Lingvay, I., Messiah, S. E., & Almandoz, J. P. (2023) · Obesity · doi:10.1002/oby.23736 · Cited by 86
Suliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13672 · Cited by 86
“Therefore, our results indicate that liraglutide 3 mg can be a useful adjunctive option in patients who did not have an optimal response to, or have regained weight after bariatric surgery, as shown in previous studies.(11) Liraglutide at the lower doses of 1.”
ResultBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
The limits and challenges of antiobesity pharmacotherapy
Gadde, K. M., & Atkins, K. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1748599 · Cited by 65
Toth, A. T., Gomez, G., Shukla, A. P., Pratt, J. S., Cena, H., Biino, G., Aronne, L. J., & Stanford, F. C. (2018) · Children · doi:10.3390/children5090116 · Cited by 57
Self-citationHorber, F. F., & Steffen, R. (2021) · Obesity Surgery · doi:10.1007/s11695-020-04856-y · Cited by 57
“Therefore, liraglutide seems to be the most efficient drug to date to treat inadequate weight loss or weight regain after bariatric operations [19].”
BackgroundInfluentialPharmacotherapy for Obesity—Trends Using a Population Level National Database
Elangovan, A., Shah, R., & Smith, Z. L. (2021) · Obesity Surgery · doi:10.1007/s11695-020-04987-2 · Cited by 56
Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes
Gazda, C. L., Clark, J. D., Lingvay, I., & Almandoz, J. P. (2021) · Obesity · doi:10.1002/oby.23146 · Cited by 56
“By comparison, their study did not include individuals with a history of adjustable gastric banding, and <15% of their cohort were treated with a GLP1RA (12% liraglutide and 2% exenatide) (20).”
Use of weight loss medications in patients after bariatric surgery.
Redmond, I. P., Shukla, A. P., & Aronne, L. J. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00425-1 · Cited by 50
Self-citationElhag, W., & El Ansari, W. (2022) · Obesity Surgery · doi:10.1007/s11695-021-05884-y · Cited by 49
Muratori, F., Vignati, F., Di Sacco, G., Gavazzi, L., Pellegrino, D., & Del Prete, M. (2022) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-022-01403-9 · Cited by 49
Current concepts in management of weight regain following bariatric surgery
Shukla, A. P., He, D., Saunders, K. H., Andrew, C., & Aronne, L. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1447922 · Cited by 49
“[RYGB = 258; sleeve gastrectomy = 61] treated at two academic institutions [54].”
BackgroundSelf-citationIstfan, N. W., Anderson, W. A., Hess, D. T., Yu, L., Carmine, B., & Apovian, C. M. (2020) · Obesity · doi:10.1002/oby.22786 · Cited by 43
“Few other studies have demonstrated that AOMs remain effective after bariatric surgery (31-36).”
BackgroundPharmacologic management of weight regain following bariatric surgery.
Lucas, E., Simmons, O., Tchang, B., & Aronne, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043595 · Cited by 41
“12 months BP to AOM: 38 months Weight Change Not app RYGB SG GB -3.2 kg -4.6% WL -0.3 kg -0.3% WL -4.6 kg -4.6% WL Stanford 2017 {27986587} Retrospective study of 319 patients with WR or inadequate weight loss and exposed to 1 or more AOMs AOMs evaluated: Ph, Top, Ph-Top, Metf, Bup, Bup-Nal,…”
BackgroundMethodInfluentialSelf-citationReal world use of tirzepatide in the treatment of type 2 diabetes in an Arab population
Buckley, A., Suliman, S., Allum, M., Mohammed, N., Lessan, N., le Roux, C. W., & Suliman, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15680 · Cited by 29
“16,17 We observed significant improvements in blood pressure and lipid profile after the initiation of tirzepatide.”
Care of the Patient After Metabolic and Bariatric Surgery
Bramante, C., Wise, E., & Chaudhry, Z. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202205170 · Cited by 28
Vosburg, R. W., El Chaar, M., El Djouzi, S., Docimo, S., Choi, D., LaMasters, T., Srivastava, G., Shukla, A. P., Oviedo, R. J., Fitch, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.07.002 · Cited by 24
Self-citationElhag, W., El Ansari, W., Abdulrazzaq, S., Elsherif, M., & Mustafa, I. (2019) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2019.07.024 · Cited by 15
Weight Regain After Bariatric/Metabolic Surgery: A Wake‐Up Call
Cohen, R. V., & Cummings, D. E. (2020) · Obesity · doi:10.1002/oby.22822 · Cited by 9
Metadata
- Authors
- Stanford, F. C., Alfaris, N., Gomez, G., Ricks, E. T., Shukla, A. P., Corey, K. E., Pratt, J. S., Pomp, A., Rubino, F., & Aronne, L. J.
- Venue
- Surgery for Obesity and Related Diseases
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 13
- Issue
- 3
- Pages
- 491-500
- ISSN
- 1550-7289 (ISSN-L)
- OpenAlex
- W2546249836
- Cited by
- 206
- References
- 18
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.